Using the cancer registry to meet the Commission on Cancer clinical trials accrual standard.
Clinical trials are an important tool for innovation in cancer treatments. Therefore, accrual into trials has been highlighted for Commission on Cancer (CoC)-accredited hospital programs. The current Standard 5.21 and Standard 1.92 which take effect in 2015 require a minimum percentage of patient enrollment for compliance, as well as an opportunity for commendation at a higher percentage. The standards do not define a role for the hospital cancer registry staff but, at C/NET Solutions, we believe that the data collection and management efforts of the registry can be leveraged to effectively screen patients for clinical trials accrual.